LUNGCAABS · Utility of tumor antigens as therapeutic and diagnostic tools
FP6 — Marie Curie Actions (Human Resources and Mobility)
- Duration
- 2007-02-01 → 2009-01-31
- EU contribution
- €80,000
- Participants
- 1
- Scheme
- EIF
Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.
Results in brief
Final Activity Report Summary - LUNGCAABS (Utility of tumor antigens as therapeutic and diagnostic tools)
The project aimed the characterisation of naturally occurring immune responses against tumours elicited by the host (patient). We successfully showed that an immune response against the tumour-associated protein SOX2, associates with longer survival in patients with small cell lung cancer. Most importantly, we showed that this response is an independent prognostic criteria indicating that regardless of the patient's clinical state, the presence of antibodies is a marker for longer survival. These results have important implications for immunotherapy for small cell lung cancer patients.
Data: CORDIS, © European Union
Project objective
The serological profiling of anti-tumour associated antigen responses through large- scale efforts has identified over 2000 antigens. Our preliminary results show a correlation between antibody responses against a number of these with parameters indicative of indolent disease and with longer overall survival in lung cancer patients. The first aim of this project is to extend and establish these observations. Since these are antigens primarily expressed by tissues of neuroectodermal origin, we want to prove the absence of an association of antibodies against them and autoimmune paraneoplastic neuronal degeneration.
Original text from CORDIS.
Participants
- BILKENT UNIVERSITESI · ANKARACoordinatorCity levelTürkiye
Links
Data: CORDIS, © European Union